Seripa D et al., 2016: Independent review of tau-directed Alzheimer's therapies summarising that methylene blue (methylthioninium chloride) failed to show overall benefit in a 24-week phase 2 trial at 69-228 mg/day, and that the follow-up compound TRx0237 (leuco-methylthioninium) was claimed by its developers to be more bioavailable and less toxic.
A follow-up compound (TRx0237) claimed to be more bioavailable and less toxic than MT, is now being developed.
Seripa D et al., 2016: Independent review of tau-directed Alzheimer's therapies summarising that methylene blue (methylthioninium chloride) failed to show overall benefit in a 24-week phase 2 trial at 69-228 mg/day, and that the follow-up compound TRx0237 (leuco-methylthioninium) was claimed by its developers to be more bioavailable and less toxic. Study type: review.
